Alopecia Universalis (AU)

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Alopecia Universalis (AU) trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

RecruitingPhase 4

NCT07381556

Cyclosporine Or Methotrexate for Pediatric Alopecia Areata: Routine Clinical Care Effectiveness Study

Rationale: Since the introduction of Janus kinase (JAK) inhibitors, there has been a significant advancement in the treatment of pediatric alopecia areata. Elig…

Netherlands50 participantsStarted 2025-11-01

Treatment: Methotrexate, Cyclosporin (CSA)

All recent trials (5 shown)

AVAILABLENot Applicable

NCT05522556

Pre-approval Single-patient Expanded Access for Ritlecitinib (PF-06651600)

Provide pre-approval single patient Expanded Access (compassionate use) of Ritlecitinib for patients.

Location not specified

Treatment: Ritlecitinib

TerminatedPhase 2

NCT03759340

ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT)

This is an open label study of ATI-502 Topical Solution for the treatment of AA, AU, and AT with the following goals: * To assess the safety, tolerability, and…

United States56 participantsStarted 2019-01-15

Treatment: ATI 502 0.46% Topical Solution

Alopecia Universalis (AU)

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

Cyclosporine Or Methotrexate for Pediatric Alopecia Areata: Routine Clinical Care Effectiveness Study

All recent trials (5 shown)

Pre-approval Single-patient Expanded Access for Ritlecitinib (PF-06651600)

ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT)

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

Cyclosporine Or Methotrexate for Pediatric Alopecia Areata: Routine Clinical Care Effectiveness Study

All recent trials (5 shown)

Pre-approval Single-patient Expanded Access for Ritlecitinib (PF-06651600)

ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT)

Safety and Pharmacokinetic Study of ATI-50002 in Subjects With Alopecia Universalis (AU) and Alopecia Totalis (AT)

Tofacitnib for the Treatment of Alopecia Areata and Variants